Trial intelligence / Profile preview

Liraglutide for non-alcoholic steatohepatitis in overweight adults

2009-016761-29Phase 2Completed

Sponsor: University of Birmingham
Start: Apr 2010
Modality: Peptides
Countries: 1

Overview

Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Liraglutide with Placebo (2 arms). Primary endpoint: Improvement in liver histology. Started Apr 2010; status: completed.

Drugs

liraglutide

Conditions

metabolic dysfunction-associated steatohepatitis (MASH)

Beyond the preview

Go deeper on 2009-016761-29.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-016761-29.